Overexpression of malignant brain tumor domain containing protein 1 predicts a poor prognosis of prostate cancer

Wu,Wanhua; Bai,Shoumin; Zhu,Dingjun; Li,Kaiwen; Dong,Wen; He,Wang; Peng,Shengmeng; Lai,Yiming; Wang,Qiong; Guo,Zhenghui; Liu,Leyuan; Huang,Hai

doi:10.3892/ol.2019.10109

Overexpression of malignant brain tumor domain containing protein 1 predicts a poor prognosis of prostate cancer

Authors:
- Wanhua Wu
- Shoumin Bai
- Dingjun Zhu
- Kaiwen Li
- Wen Dong
- Wang He
- Shengmeng Peng
- Yiming Lai
- Qiong Wang
- Zhenghui Guo
- Leyuan Liu
- Hai Huang
View Affiliations

Affiliations: Department of Urology, The Sun Yat‑Sen Memorial Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510120, P.R. China, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, TX 77030, USA
Published online on: March 5, 2019 https://doi.org/10.3892/ol.2019.10109
Pages: 4640-4646

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant brain tumor domain containing protein 1 (MBTD1) is a member of the polycomb group protein family that is associated with tumorigenesis. The present study investigated the role of MBTD1 within defined clinicopathological parameters and the prognosis of patients with prostate cancer (PCa). A human tissue microarray containing samples from 71 patients with PCa and seven healthy donors was employed for immunohistochemistry (IHC). The clinicopathological characteristics and prognostic value of MBTD1 were investigated using a dataset of 499 patients from The Cancer Genome Atlas (TCGA). IHC illustrated that the levels of MBTD1 protein were enhanced and markedly associated with aggressive clinical stage and advanced tumor invasion, distant metastasis and lymph node metastasis in patients with PCa. In the TCGA data set, the level of MBTD1 was found to positively correlate with the prostate‑specific antigen level, Gleason score and distant metastasis. The multivariate analysis of Cox regression revealed that the levels of MBTD1 may act as an independent prognostic factor for low non‑biochemical, recurrence‑free survival. In conclusion, MBTD1 was overexpressed in PCa tissues and is associated with aggressive clinicopathological characteristics. It may therefore act as a novel prognostic factor and diagnostic marker in PCa.

View Figures

View References

1	Dy GW, Gore JL, Forouzanfar MH, Naghavi M and Fitzmaurice C: Global burden of urologic cancers, 1990–2013. Eur Urol. 71:437–446. 2017. View Article : Google Scholar : PubMed/NCBI
2	Fenner A: Prostate cancer: AS-contemplation, not intervention. Nat Rev Oncol. 12:5952015.
3	Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ and Carter HB: Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol. 33:3379–3385. 2016. View Article : Google Scholar
4	Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG and de Bono JS: Prostate cancer. Lancet. 387:70–82. 2016. View Article : Google Scholar : PubMed/NCBI
5	Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, Wirth M and Mottet N; European Association of Urology, : Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol. 64:347–354. 2013. View Article : Google Scholar : PubMed/NCBI
6	Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O and Bray F: International variation in prostate cancer incidence and mortality rates. Eur Urol. 61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
7	Kattan MW, Vickers AJ, Yu C, Bianco FJ, Cronin AM, Eastham JA, Klein EA, Reuther AM, Edson Pontes J and Scardino PT: Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer. 115:1005–1010. 2009. View Article : Google Scholar : PubMed/NCBI
8	Mills AA: Throwing the cancer switch: Reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer. 10:669–682. 2010. View Article : Google Scholar : PubMed/NCBI
9	Eryilmaz J, Pan P, Amaya MF, Allali-Hassani A, Dong A, Adams-Cioaba MA, Mackenzie F, Vedadi M and Min J: Structural studies of a four-MBT repeat protein MBTD1. PLoS One. 4:e72742009. View Article : Google Scholar : PubMed/NCBI
10	Wismar J, Loffler T, Habtemichael N, Vef O, Geissen M, Zirwes R, Altmeyer W, Sass H and Gateff E: The Drosophila melanogaster tumor suppressor gene lethal(3)malignant brain tumor encodes a proline-rich protein with a novel zinc finger. Mech Dev. 53:141–154. 1995. View Article : Google Scholar : PubMed/NCBI
11	Jacquet K, Fradet-Turcotte A, Avvakumov N, Lambert JP, Roques C, Pandita RK, Paquet E, Herst P, Gingras AC, Pandita TK, et al: The TIP60 complex regulates bivalent chromatin recognition by 53BP1 through direct H4K20me binding and H2AK15 acetylation. Mol Cell. 62:409–421. 2016. View Article : Google Scholar : PubMed/NCBI
12	Dewaele B, Przybyl J, Quattrone A, Finalet Ferreiro J, Vanspauwen V, Geerdens E, Gianfelici V, Kalender Z, Wozniak A, Moerman P, et al: Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int J Cancer. 134:1112–1122. 2014. View Article : Google Scholar : PubMed/NCBI
13	de Rooij JD, van den Heuvel-Eibrink MM, Kollen WJ, Sonneveld E, Kaspers GJ, Beverloo HB, Fornerod M, Pieters R and Zwaan CM: Recurrent translocation t(10;17)(p15;q21) in minimally differentiated acute myeloid leukemia results in ZMYND11/MBTD1 fusion. Genes Chromosomes Cancer. 55:237–241. 2016. View Article : Google Scholar : PubMed/NCBI
14	De Braekeleer E, Auffret R, Douet-Guilbert N, Basinko A, Le Bris MJ, Morel F and De Braekeleer M: Recurrent translocation (10;17)(p15;q21) in acute poorly differentiated myeloid leukemia likely results in ZMYND11-MBTD1 fusion. Leuk Lymphoma. 55:1189–1190. 2014. View Article : Google Scholar : PubMed/NCBI
15	Klymenko T, Papp B, Fischle W, Köcher T, Schelder M, Fritsch C, Wild B, Wilm M and Müller J: A Polycomb group protein complex with sequence-specific DNA-binding and selective methyl-lysine-binding activities. Genes Dev. 20:1110–1122. 2006. View Article : Google Scholar : PubMed/NCBI
16	Grimm C, de Ayala Alonso AG, Rybin V, Steuerwald U, Ly-Hartig N, Fischle W, Müller J and Müller CW: Structural and functional analyses of methyl-lysine binding by the malignant brain tumour repeat protein Sex comb on midleg. EMBO Rep. 8:1031–1037. 2007. View Article : Google Scholar : PubMed/NCBI
17	Chen X, Xie W, Gu P, Cai Q, Wang B, Xie Y, Dong W, He W, Zhong G, Lin T and Huang J: Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation. Sci Rep. 5:82932015. View Article : Google Scholar : PubMed/NCBI
18	Ma X, Du T, Zhu D, Chen X, Lai Y, Wu W, Wang Q, Lin C, Li Z, Liu L and Huang H: High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer. Oncol Lett. 16:6749–6755. 2018.PubMed/NCBI
19	Cimino-Mathews A, Subhawong AP, Illei PB, Sharma R, Halushka MK, Vang R, Fetting JH, Park BH and Argani P: GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Hum Pathol. 44:1341–1349. 2013. View Article : Google Scholar : PubMed/NCBI
20	Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP and Akslen LA: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 24:268–273. 2006. View Article : Google Scholar : PubMed/NCBI
21	Gu P, Chen X, Xie R, Han J, Xie W, Wang B, Dong W, Chen C, Yang M, Jiang J, et al: lncRNA HOXD-AS1 regulates proliferation and chemo-resistance of castration-resistant prostate cancer via recruiting WDR5. Mol Ther. 25:1959–1973. 2017. View Article : Google Scholar : PubMed/NCBI
22	Chen X, Gu P, Xie R, Han J, Liu H, Wang B, Xie W, Xie W, Zhong G, Chen C, et al: Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancer. J Cell Mol Med. 21:1266–1279. 2017. View Article : Google Scholar : PubMed/NCBI
23	Nady N, Krichevsky L, Zhong N, Duan S, Tempel W, Amaya MF, Ravichandran M and Arrowsmith CH: Histone recognition by human malignant brain tumor domains. J Mol Biol. 423:702–718. 2012. View Article : Google Scholar : PubMed/NCBI
24	Wang YQ, Wang PY, Wang YT, Yang GF, Zhang A and Miao ZH: An update on Poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: Opportunities and challenges in cancer therapy. J Med Chem. 59:9575–9598. 2016. View Article : Google Scholar : PubMed/NCBI
25	Kluzek K, Bialkowska A, Koczorowska A and Zdzienicka MZ: Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy. Postepy Hig Med Dosw (Online). 66:372–384. 2012. View Article : Google Scholar : PubMed/NCBI
26	Gao D, Herman JG and Guo M: The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. Oncotarget. 7:37331–37346. 2016.PubMed/NCBI
27	Kirmizis A, Bartley SM and Farnham PJ: Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther. 2:113–121. 2003.PubMed/NCBI
28	Ma X, Huang J, Tian Y, Chen Y, Yang Y, Zhang X, Zhang F and Xue L: Myc suppresses tumor invasion and cell migration by inhibiting JNK signaling. Oncogene. 36:3159–3167. 2017. View Article : Google Scholar : PubMed/NCBI